ASTRAZEN
Astrazeneca Pharma India Limited
Each stock's 10,000-path forecast, rendered as light.
Astrazeneca Pharma India Limited (ASTRAZEN) Stock Analysis & Case Study
Is ASTRAZEN a good buy? The data-driven verdict.
Astrazeneca Pharma India Limited (ASTRAZEN) trades at ₹8,191,on the numbers it worth a closer look, a Downstox Snapshot Score of 60/100.
On the numbers, Astrazeneca Pharma India Limited (ASTRAZEN) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 107.0× earnings, ROE of 23.3%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ASTRAZEN fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ASTRAZEN ranks against the 2,373 companies in our screener
- ASTRAZEN's market cap of 20,478 Cr ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's book value of ₹349 ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's promoter holding of 75.0% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's 3-year profit (PAT) growth of 15.0% ranks in the 49th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's 3-year revenue growth of 31.0% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's debt-to-equity ratio of 0.13x is lower than 72% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ASTRAZEN overvalued? ASTRAZEN P/E vs peers
ASTRAZEN trades at 107.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ASTRAZEN share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of ASTRAZEN history (21%/yr drift, 34%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ASTRAZEN 2027 | ₹5,790 | ₹8,915 | ₹13,726 | +9% |
| ASTRAZEN 2028 | ₹5,260 | ₹9,702 | ₹17,897 | +18% |
| ASTRAZEN 2029 | ₹4,994 | ₹10,559 | ₹22,328 | +29% |
| ASTRAZEN 2030 | ₹4,753 | ₹11,492 | ₹27,787 | +40% |
| ASTRAZEN 2031 | ₹4,641 | ₹12,508 | ₹33,707 | +53% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ASTRAZEN goes up, or doubles?
The bull case for ASTRAZEN
- ASTRAZEN's return on equity of 23.3% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ASTRAZEN's return on capital employed of 29.3% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹8,915 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹22,328.
The bear case & risks
- ASTRAZEN's P/E of 107.0x is lower than 10% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 23.5× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹4,994.
ASTRAZEN volatility & expected range, how bumpy is the ride?
Over the last 9.8 years ASTRAZEN compounded at 21%/year with annualized volatility of 34%. That volatility implies a 1-year 80% range of ₹5,790-₹13,726, the honest backbone behind any single price target.
ASTRAZEN price forecast, the full 60-month probability fan
ASTRAZEN price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ASTRAZEN hits common targets within the simulated horizon?
Full multi-horizon detail on the ASTRAZEN price target & forecast page.
ASTRAZEN Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ASTRAZEN scores 6/8, mixed financial health.
ASTRAZEN MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy ASTRAZEN with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| ZerodhaCHEAPEST | 29.20% | 3.4× |
| Groww | 29.28% | 3.4× |
| Dhan | 29.20% | 3.4× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 29.34% | 3.4× |
| Pocketful | 29.45% | 3.4× |
| Anand RathiCHEAPEST | 29.20% | 3.4× |
| Bajaj Broking | 36.00% | 2.8× |
| Share India | 29.28% | 3.4× |
Compare every broker on the ASTRAZEN MTF page.
About Astrazeneca Pharma India Limited: sector, index & market-cap context
Astrazeneca Pharma India Limited (ASTRAZEN) is a mid-cap NSE-listed company, with a market capitalisation of ₹20,478 Cr. See more stocks on our screener.
How the ASTRAZEN Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Astrazeneca Pharma India Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ASTRAZEN analysis, FAQs
Is Astrazeneca Pharma India Limited (ASTRAZEN) a good buy?
On the numbers, Astrazeneca Pharma India Limited (ASTRAZEN) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 107.0× earnings, ROE of 23.3%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ASTRAZEN overvalued or undervalued?
ASTRAZEN trades at 107.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the ASTRAZEN share price target for 2031?
ASTRAZEN's probability-weighted 2031 median target is ₹12,508, with an 80% range of ₹4,641-₹33,707 (10,000-path Monte-Carlo).
What is the probability ASTRAZEN doubles in 5 years?
The modelled probability of ASTRAZEN reaching ₹16,382 (2×) within 5 years is 36%.
What is the bull case for ASTRAZEN?
ASTRAZEN's return on equity of 23.3% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ASTRAZEN's return on capital employed of 29.3% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹8,915 (+9%).
What are the risks in ASTRAZEN?
ASTRAZEN's P/E of 107.0x is lower than 10% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 23.5× price-to-book means most of the value is intangible/expectations, not assets on the books.